Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lipocine Inc (LPCN)

1.42   0.05 (3.65%) 09-27 22:03
Open: 1.36 Pre. Close: 1.37
High: 1.45 Low: 1.35
Volume: 1,158,238 Market Cap: 93M
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 10 full-time employees. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The firm's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.453 - 1.463 1.463 - 1.472
Low: 1.327 - 1.339 1.339 - 1.35
Close: 1.401 - 1.42 1.42 - 1.438

Technical analysis

as of: 2020-09-25 4:32:14 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.98     One year: 2.38
Support: Support1: 1.13    Support2: 0.94
Resistance: Resistance1: 1.69    Resistance2: 2.04
Pivot: 1.41
Moving Average: MA(5): 1.47     MA(20): 1.41
MA(100): 1.32     MA(250): 1.08
MACD: MACD(12,26): -0.04     Signal(9): -0.06
Stochastic oscillator: %K(14,3): 56.46     %D(3): 67.46
RSI: RSI(14): 45.55
52-week: High: 3.25  Low: 0.30  Change(%): -49.5
Average Vol(K): 3-Month: 432660  10-Days: 290917

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
LPCN has closed below upper band by 47.8%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 21 Sep 2020
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study - PRNewswire

Thu, 17 Sep 2020
Lipocine Inc. (NASDAQ:LPCN) is Waving the Bull Flag - The Oracle Dispatch

Tue, 15 Sep 2020
Should You Buy Lipocine Inc (LPCN) Stock After it Has Gained 12.50% in a Week? - InvestorsObserver

Tue, 15 Sep 2020
Do Lipocine Inc. (LPCN) beta value of 0.54 signposts another twist? - The InvestChronicle

Mon, 14 Sep 2020
Riding the Trend or Protecting Profits | Lipocine Inc. (LPCN) - The News Heater

Fri, 11 Sep 2020
No matter how cynical the overall market is Lipocine Inc. (LPCN) performance over the last week is recorded -7.35% - News Daemon

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 66
Shares Float (M) 64
% Held by Insiders 3.68
% Held by Institutions 17.76
Shares Short (K) 4,460
Shares Short P. Month (K) 1,730

Stock Financials

EPS -0.505
EPS Est This Year -0.960
EPS Est Next Year -0.720
Book Value (p.s.) 0.210
Profit Margin
Operating Margin -9239.03
Return on Assets (ttm) -44.2
Return on Equity (ttm) -161.3
Qtrly Rev. Growth
Gross Profit (p.s.) -0.077
Sales Per Share 0.003
EBITDA (p.s.) -0.232
Qtrly Earnings Growth
Operating Cash Flow (M) -14
Levered Free Cash Flow (M) -8

Stock Valuations

PE Ratio -2.81
PEG Ratio
Price to Book value 6.76
Price to Sales 565.37
Price to Cash Flow -6.88

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.